Sarkis Mazmanian
Professor of microbiology
California Institute of Technology
From this contributor
Remembering Paul Patterson (1944-2014)
Paul H. Patterson, a transformative figure in autism research, died on 25 June. His groundbreaking discoveries advanced novel paradigms in neuroscience and immunology, and introduced concepts that will continue to be developed by researchers worldwide.
The case for using ‘prebiotics’
Prebiotics — nutrients that promote the growth of some beneficial gut bacteria — can influence brain chemistry and behavior. New findings suggest prebiotics as treatments for people with neurological disorders, say Sarkis Mazmanian and Gil Sharon.
Explore more from The Transmitter
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.